{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:20:21Z","timestamp":1794525621743,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Syphilis is an infectious disease that is at least discussed to be premalignant. This potential, combined with its general pathological impact, raises the question if syphilis increases mortality in oral cancer patients. The aim of the study was to assess if the five-year survival rates among patients suffering from oral squamous cell carcinoma (OSCC) with (cohort I) and without association with syphilis (cohort II) differ.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective clinical data of patients diagnosed with OSCC (International Classification of Diseases [ICD]-10 codes C01\u201306) within the past 20\u2009years from the access date September 25, 2021 were retrieved from the TriNetX network (TriNetX, Cambridge, Massachusetts, USA) to gain initial cohort 0. Subjects also diagnosed with syphilis (ICD-10 codes A51\u201353) were assigned to cohort I. Cohort II was comprised of the remaining individuals of cohort 0 by creating a group with the same number of patients as cohort I, and by matching for age and gender. Subsequently, Kaplan-Meier analysis and Cox proportional hazards regression were performed, and risk, odds and hazard ratios were calculated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of a total of 73,736 patients in cohort 0, 199 individuals were each assigned to cohort I and II. During the five-year period after tumor diagnosis, 39 and 30 patients in cohort I and II died. The five-year survival probabilities did not significantly differ between the cohorts (I vs. II\u2009=\u200974.19% vs. 75.01%; <jats:italic>p<\/jats:italic>\u00a0=\u20090.52; Log-Rank test), nor the risk of dying (I vs. II\u2009=\u200919.6% vs. 15.08%; risk difference\u2009=\u20094.52%; <jats:italic>p<\/jats:italic>\u00a0=\u20090.23). The calculated risk, odds and hazard ratios were 1.3 (95% confidence interval [CI]\u2009=\u20090.84; 2.00), 1.37 (95% CI\u2009=\u20090.81; 2.31) and 1.17 (95% CI\u2009=\u20090.73; 1.88), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The obtained results indicate that the survival rate of individuals with OSCC might not be negatively influenced if syphilis is present\/associated. However, the results need to be interpreted cautiously due to limitations related to the retrospective approach, especially as data on the tumor staging were not accessible.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Due to the retrospective nature of the study, no registration was necessary.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09583-4","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T04:26:32Z","timestamp":1650947192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of five-year survival rates among patients with oral squamous cell carcinoma with and without association with syphilis: a retrospective case-control study"],"prefix":"10.1186","volume":"22","author":[{"given":"Moritz","family":"Hertel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Hagedorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Maria","family":"Schmidt-Westhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Dommisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Heiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Preissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Preissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"9583_CR1","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(16)32411-4","volume":"389","author":"EW Hook 3rd","year":"2017","unstructured":"Hook EW 3rd. Syphilis. Lancet. 2017;389:1550\u20137.","journal-title":"Lancet"},{"key":"9583_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.joms.2013.07.015","volume":"72","author":"M Hertel","year":"2014","unstructured":"Hertel M, Matter D, Schmidt-Westhausen AM, Bornstein MM. Oral syphilis: a series of 5 cases. J Oral Maxillofac Surg. 2014;72:338\u201345.","journal-title":"J Oral Maxillofac Surg"},{"key":"9583_CR3","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1111\/odi.13704","volume":"27","author":"S Warnakulasuriya","year":"2021","unstructured":"Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, Bagan JV, Gonzalez-Moles MA, Kerr AR, et al. Oral potentially malignant disorders: a consensus report from an international seminar on nomenclature and classification, convened by the WHO collaborating Centre for Oral Cancer. Oral Dis. 2021;27:1862\u201380.","journal-title":"Oral Dis"},{"key":"9583_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0714.1983.tb00312.x","volume":"12","author":"WH Binnie","year":"1983","unstructured":"Binnie WH, Rankin KV, Mackenzie IC. Etiology of oral squamous cell carcinoma. J Oral Pathol. 1983;12:11\u201329.","journal-title":"J Oral Pathol"},{"key":"9583_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2165\/00128071-200102040-00005","volume":"2","author":"JJ Sciubba","year":"2001","unstructured":"Sciubba JJ. Oral cancer. The importance of early diagnosis and treatment. Am J Clin Dermatol. 2001;2:239\u201351.","journal-title":"Am J Clin Dermatol"},{"key":"9583_CR6","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1177\/000348945506400228","volume":"64","author":"SG Castigliano","year":"1955","unstructured":"Castigliano SG. Syphilis and oral cancer. Ann Otol Rhinol Laryngol. 1955;64:608\u201316.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"9583_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/ije\/23.2.381","volume":"23","author":"AM Michalek","year":"1994","unstructured":"Michalek AM, Mahoney MC, McLaughlin CC, Murphy D, Metzger BB. Historical and contemporary correlates of syphilis and cancer. Int J Epidemiol. 1994;23:381\u20135.","journal-title":"Int J Epidemiol"},{"key":"9583_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/0253-7184.156745","volume":"36","author":"S Rahima","year":"2015","unstructured":"Rahima S, Riyaz N, Latheef EN, Shyni PM. Squamous cell carcinoma on a syphilitic gumma: A unique presentation. Indian J Sex Transm Dis AIDS. 2015;36:89\u201391.","journal-title":"Indian J Sex Transm Dis AIDS"},{"key":"9583_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0266-4356(95)90046-2","volume":"33","author":"AJ Dickenson","year":"1995","unstructured":"Dickenson AJ, Currie WJ, Avery BS. Screening for syphilis in patients with carcinoma of the tongue. Br J Oral Maxillofac Surg. 1995;33:319\u201320.","journal-title":"Br J Oral Maxillofac Surg"},{"key":"9583_CR10","doi-asserted-by":"crossref","unstructured":"Sasahira T, Kirita T. Hallmarks of Cancer-related newly prognostic factors of Oral squamous cell carcinoma. Int J Mol Sci. 2018;19:2413\u201334.","DOI":"10.3390\/ijms19082413"},{"key":"9583_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41392-021-00689-y","volume":"6","author":"C Mura","year":"2021","unstructured":"Mura C, Preissner S, Nahles S, Heiland M, Bourne PE, Preissner R. Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients. Signal Transduct Target Ther. 2021;6:267.","journal-title":"Signal Transduct Target Ther"},{"key":"9583_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12916-020-01851-z","volume":"18","author":"U Seeland","year":"2020","unstructured":"Seeland U, Coluzzi F, Simmaco M, Mura C, Bourne PE, Heiland M, et al. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC Med. 2020;18:369.","journal-title":"BMC Med"},{"key":"9583_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ad.2014.06.007","volume":"106","author":"CE Morales-Munera","year":"2015","unstructured":"Morales-Munera CE, Fuentes-Finkelstein PA, Vall MM. Update on the diagnosis and treatment of syphilis. Actas Dermosifiliogr. 2015;106:68\u20139.","journal-title":"Actas Dermosifiliogr"},{"key":"9583_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0030-6665(20)32492-0","volume":"12","author":"SL Sellars","year":"1979","unstructured":"Sellars SL. Epidemiology of oral cancer. Otolaryngol Clin N Am. 1979;12:45\u201355.","journal-title":"Otolaryngol Clin N Am"},{"key":"9583_CR15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1601-0825.2009.01563.x","volume":"15","author":"C Scully","year":"2009","unstructured":"Scully C, Bagan J. Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis. 2009;15:388\u201399.","journal-title":"Oral Dis"},{"key":"9583_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/014556130608500201","volume":"85","author":"L Thompson","year":"2006","unstructured":"Thompson L. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J. 2006;85:74.","journal-title":"Ear Nose Throat J"},{"key":"9583_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.oraloncology.2008.05.008","volume":"45","author":"SN Rogers","year":"2009","unstructured":"Rogers SN, Brown JS, Woolgar JA, Lowe D, Magennis P, Shaw RJ, et al. Survival following primary surgery for oral cancer. Oral Oncol. 2009;45:201\u201311.","journal-title":"Oral Oncol"},{"key":"9583_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.oraloncology.2010.01.019","volume":"46","author":"BJ Braakhuis","year":"2010","unstructured":"Braakhuis BJ, Bloemena E, Leemans CR, Brakenhoff RH. Molecular analysis of surgical margins in head and neck cancer: more than a marginal issue. Oral Oncol. 2010;46:485\u201391.","journal-title":"Oral Oncol"},{"key":"9583_CR19","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/ijc.25523","volume":"128","author":"AP Graveland","year":"2011","unstructured":"Graveland AP, Golusinski PJ, Buijze M, Douma R, Sons N, Kuik DJ, et al. Loss of heterozygosity at 9p and p53 immunopositivity in surgical margins predict local relapse in head and neck squamous cell carcinoma. Int J Cancer. 2011;128:1852\u20139.","journal-title":"Int J Cancer"},{"key":"9583_CR20","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12094-012-0867-2","volume":"14","author":"M Grimm","year":"2012","unstructured":"Grimm M. Prognostic value of clinicopathological parameters and outcome in 484 patients with oral squamous cell carcinoma: microvascular invasion (V+) is an independent prognostic factor for OSCC. Clin Transl Oncol. 2012;14:870\u201380.","journal-title":"Clin Transl Oncol"},{"key":"9583_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S1368-8375(02)00030-1","volume":"39","author":"JA Woolgar","year":"2003","unstructured":"Woolgar JA, Rogers SN, Lowe D, Brown JS, Vaughan ED. Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. Oral Oncol. 2003;39:130\u20137.","journal-title":"Oral Oncol"},{"key":"9583_CR22","doi-asserted-by":"publisher","first-page":"eAO4248","DOI":"10.1590\/s1679-45082018ao4248","volume":"16","author":"JDS Moro","year":"2018","unstructured":"Moro JDS, Maroneze MC, Ardenghi TM, Barin LM, Danesi CC. Oral and oropharyngeal cancer: epidemiology and survival analysis. Einstein (Sao Paulo). 2018;16:eAO4248.","journal-title":"Einstein (Sao Paulo)"},{"key":"9583_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.oraloncology.2019.02.001","volume":"90","author":"DK Zanoni","year":"2019","unstructured":"Zanoni DK, Montero PH, Migliacci JC, Shah JP, Wong RJ, Ganly I, et al. Survival outcomes after treatment of cancer of the oral cavity (1985-2015). Oral Oncol. 2019;90:115\u201321.","journal-title":"Oral Oncol"},{"key":"9583_CR24","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1600-0463.2010.02624.x","volume":"118","author":"CB Lajer","year":"2010","unstructured":"Lajer CB, von Buchwald C. The role of human papillomavirus in head and neck cancer. APMIS. 2010;118:510\u20139.","journal-title":"APMIS"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09583-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09583-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09583-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T04:26:58Z","timestamp":1650947218000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09583-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9583"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09583-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"assertion":[{"value":"24 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Administrative access to the database was granted by TriNetX. All methods were carried out in accordance with relevant guidelines and regulations. All HCOs from which data were transmitted to TriNetX obtained informed consent in written from all patients and\/or their legal guardians. TriNetX is compliant with the Health Insurance Portability and Accountability Act (HIPAA), the US federal law which protects the privacy and security of healthcare data. TriNetX is certified to the ISO 27001:2013 standard and maintains an Information Security Management System (ISMS) to ensure the protection of the healthcare data it has access to and to meet the requirements of the HIPAA Security Rule. Any data displayed on the TriNetX Platform in aggregate form, or any patient level data provided in a data set generated by the TriNetX Platform, only contains de-identified data as per the de-identification standard defined in Section \u00a7164.514(a) of the HIPAA Privacy Rule. The process by which the data is de-identified is attested to through a formal determination by a qualified expert as defined in Section \u00a7164.514(b) [] of the HIPAA Privacy Rule. This formal determination by a qualified expert, refreshed in December 2020, supersedes the need for TriNetX\u2019s previous waiver from the Western Institutional Review Board (IRB). The TriNetX network contains data provided by participating Healthcare Organizations (HCOs), each of which represents and warrants that it has all necessary rights, consents, approvals and authority to provide the data to TriNetX under a Business Associate Agreement (BAA), so long as their name remains anonymous as a data source and their data are utilized for research purposes. The data shared through the TriNetX Platform are attenuated to ensure that they do not include sufficient information to facilitate the determination of which HCO contributed which specific information about a patient ().Access to the database is closed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"454"}}